Richard McCormick (R-GA) bought $1,001 - $15,000 of Abbott Laboratories (ABT) on March 19, 2026, according to a transaction report disclosed April 7, 2026. USAspending records an action by the Department of Defense on April 9, 2026, 21 days after the nearest trade, on a definitive contract (W81XWH19C0071) with Abbott Laboratories Inc. whose total value is $37.6M. McCormick sits on the House Committee on Armed Services, which oversees the Department of Defense. 2 other contracts with the company have an action inside the same 90-day window. April 9, 2026 was the latest action USAspending listed for that contract when it was pulled on September 18, 2026; the contract itself may be years older, and $37.6M is its total value, not the amount of that action. The records do not show who placed the trade or that anyone involved knew of the contract.
A lead built from public records, not a finding of wrongdoing. Each record below is checked against its source every day; a lead that stops matching is withdrawn.
Richard McCormick sits on the House Committee on Armed Services, which oversees the Department of Defense.
Linked by ticker ABT to Abbott Laboratories (ABT); USAspending recipient Abbott Laboratories Inc. (parent: Abbott Laboratories) carries the company's name. Contracts whose recipient the name check could not tie to the company are left out.
Department of Defense order N6264521F0151 with Abbott Laboratories Inc.: total value $7.2M, latest recorded action June 11, 2026 (84 days after the nearest trade). USAspending description: "CHEMISTRY/IMMUNOASSAY".
Source recordDepartment of Defense contract W81XWH19C0071 with Abbott Laboratories Inc.: total value $37.6M, latest recorded action April 9, 2026 (21 days after the nearest trade). USAspending description: "LABORATORY ASSAY FOR TRAUMATIC BRAIN INJURY".
Source recordSTOCK Act transaction report disclosed for ABT, Apr 7, 2026.
Department of Defense order N6264521F0028 with Abbott Laboratories Inc.: total value $52.9M, latest recorded action December 22, 2025 (87 days before the nearest trade). USAspending description: "ANALYZER (2), LABORATORY (1) AUTOMATION, IMMUNOASSAY- CHEMISTRY".
Source record| Type | Record |
|---|---|
| trade | Bought ABT for $1,001 - $15,000 on March 19, 2026; disclosed April 7, 2026.Source |
| contract | Department of Defense contract W81XWH19C0071 with Abbott Laboratories Inc.: total value $37.6M, latest recorded action April 9, 2026 (21 days after the nearest trade). USAspending description: "LABORATORY ASSAY FOR TRAUMATIC BRAIN INJURY".Source |
| contract | Department of Defense order N6264521F0151 with Abbott Laboratories Inc.: total value $7.2M, latest recorded action June 11, 2026 (84 days after the nearest trade). USAspending description: "CHEMISTRY/IMMUNOASSAY".Source |
| contract | Department of Defense order N6264521F0028 with Abbott Laboratories Inc.: total value $52.9M, latest recorded action December 22, 2025 (87 days before the nearest trade). USAspending description: "ANALYZER (2), LABORATORY (1) AUTOMATION, IMMUNOASSAY- CHEMISTRY".Source |
| committee | Richard McCormick sits on the House Committee on Armed Services, which oversees the Department of Defense. |
| company match | Linked by ticker ABT to Abbott Laboratories (ABT); USAspending recipient Abbott Laboratories Inc. (parent: Abbott Laboratories) carries the company's name. Contracts whose recipient the name check could not tie to the company are left out. |